Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) gapped down before the market opened on Wednesday following insider selling activity. The stock had previously closed at $17.56, but opened at $17.11. Hims & Hers Health shares last traded at $16.71, with a volume of 1,528,158 shares traded.

Specifically, CEO Andrew Dudum sold 50,361 shares of the business's stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Andrew Dudum sold 50,361 shares of the business's stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,915 shares of the business's stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $20.01, for a total value of $98,349.15. Following the completion of the transaction, the insider now owns 159,357 shares in the company, valued at approximately $3,188,733.57. The disclosure for this sale can be found here. Insiders have sold a total of 594,553 shares of company stock worth $8,454,738 over the last quarter. 17.71% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research reports. Citigroup cut Hims & Hers Health from a "buy" rating to a "neutral" rating and upped their price objective for the company from $16.00 to $20.00 in a research note on Wednesday. Jefferies Financial Group reissued a "hold" rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a "hold" rating in a report on Tuesday, May 7th. Imperial Capital raised Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price objective for the company in a report on Wednesday, February 28th. Finally, SVB Leerink assumed coverage on Hims & Hers Health in a report on Monday, February 26th. They issued a "market perform" rating and a $10.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $15.69.

Hims & Hers Health Price Performance

The stock has a fifty day moving average price of $14.06 and a 200-day moving average price of $10.97. The company has a market cap of $3.48 billion, a PE ratio of -1,660.00 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company's revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.05) earnings per share. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently modified their holdings of HIMS. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter worth $48,000. Belpointe Asset Management LLC acquired a new position in Hims & Hers Health during the third quarter worth $76,000. EMC Capital Management increased its position in Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company's stock worth $79,000 after buying an additional 5,332 shares during the last quarter. Certuity LLC acquired a new position in Hims & Hers Health during the fourth quarter worth $109,000. Finally, Corton Capital Inc. acquired a new position in Hims & Hers Health during the third quarter worth $122,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.